A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000034321
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 235
Inclusion Criteria
Not provided
Exclusion Criteria
non
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationships between sequence/interval to use EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor, and frequency/severity of interstitial lung disease
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie EGFR tyrosine kinase inhibitor-induced interstitial lung disease in non-small cell lung cancer patients?
How does immune checkpoint inhibitor therapy compare to standard-of-care treatments in managing interstitial lung disease among NSCLC patients?
Are there specific biomarkers that predict susceptibility to interstitial lung disease in non-small cell lung cancer patients receiving EGFR TKIs and immune checkpoint inhibitors?
What adverse events are commonly associated with EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors in interstitial lung disease cases?
What combination strategies or alternative drugs are being explored to mitigate interstitial lung disease in non-small cell lung cancer patients undergoing EGFR and immune therapies?